In Sentinel's proof-of-concept clinical trial involving hypertension patients, we demonstrated highly significant improvement in blood pressure control and a decrease in hospital readmissions.
As shown by the graph above, patients who did not receive any intervention for high blood pressure (red line) continued to have progressive worsening of their hypertension.
In comparison, patient who received blood pressure medication based on Sentinel's methodology, showed significant reduction in blood pressure (blue line).
Sentinel observed no adverse events with our cloud-based strategy.
Our study also showed resoundingly positive findings in many other aspects of blood pressure control.
At the beginning of our study, 43% of the patients were hypertensive. By the end of the study, only 4% of patients had high blood pressure.
Sentinel's methodology based on early blood pressure treatment showed 5 mmHg reduction in systolic blood pressure.
Adverse physical signs and symptoms such as chest pain, headache and weakness decreased by 83%.
Sentinel's approach to hypertension management decreased hospital readmission by 80% over the duration of the trial.
Sentinel's pilot study achieved improved blood pressure control among 95.8% of patient's identified to be hypertensive.
This data was presented at American Heart Association Hypertension conference in 2017. [See abstract]